COLchicin und nicht magensaftresistent beschichtetes Aspirin in der Studie zu kardiovaskulären Ergebnissen bei Patienten mit Typ-2-Diabetes (COLCOT-T2D)
COLchicin und nicht magensaftresistent beschichtetes Aspirin in der Studie zu kardiovaskulären Ergebnissen bei Patienten mit Typ-2-Diabetes (COLCOT-T2D)
To evaluate the efficacy and safety of colchicine and non-enteric coated aspirin, combined or alone, to improve cardiovascular outcomes in high-risk patients with type 2 diabetes.
Studienübersicht
Status
Status
Bedingungen
Bedingungen
Intervention / Behandlung
Intervention / Behandlung
Studientyp
Studientyp
Einschreibung (Geschätzt)
Einschreibung
Phase
Phase
- Phase 3
Kontakte und Standorte
Studienkontakt
Studienkontakt
- Name: Jean-Claude Tardif, MD, FRCPC, FACC, FCAHS
- Telefonnummer: 3612 514-376-3330
- E-Mail: Jean-Claude.Tardif@icm-mhi.org
Studieren Sie die Kontaktsicherung
- Name: Mylène Provencher, PhD
- Telefonnummer: 2133 514-461-1300
- E-Mail: Mylene.Provencher@mhicc.org
Studienorte
-
-
Western Australia
-
Bentley, Western Australia, Australien, 6102
- Rekrutierung
- Curtin University
-
Kontakt:
- Chrsitopher Reid, MD
- Telefonnummer: +61892667123
- E-Mail: christopher.reid@curtin.edu.au
-
Kontakt:
- Amy Ward
- Telefonnummer: +61892669128
- E-Mail: amy.ward@curtin.edu.au
-
-
-
-
-
Hellerup, Dänemark, 2900
- Rekrutierung
- Center for Translational Cardiology and Pragmatic Randomized Trial
-
Kontakt:
- Tor Biering-Sorensen, MD
- Telefonnummer: +45 28933590
- E-Mail: tor.biering@gmail.com
-
-
-
-
-
Helsinki, Finnland, 00029
- Rekrutierung
- Heart and Lung Center, Helsinki University Hospital and Helsinki University
-
Kontakt:
- Juha Sinisalo, MD
- Telefonnummer: +358504279007
- E-Mail: juha.sinisalo@hus.fi
-
Kontakt:
- Charlotta Henriksson
- Telefonnummer: +358 40 588 2531
- E-Mail: ext-charlotta.henriksson@hus.fi
-
-
-
-
-
Morsang-sur-Orge, Frankreich, 91930
- Rekrutierung
- Cabinet médical Les Oiseaux
-
Kontakt:
- Sarah EDJEKOUANE
- Telefonnummer: 0760622535
- E-Mail: s.edjekouane@cnge.fr
-
Kontakt:
- Alexandre MALMARTEL, MD
- Telefonnummer: 0185121830
- E-Mail: alexandre.malmartel@u-paris.fr
-
Paris, Frankreich, 75019
- Rekrutierung
- Centre de santé Kersanté Rosa Parks
-
Kontakt:
- Laurence MARRIE
- Telefonnummer: 0183792816
-
-
Aveyron
-
Luc-la-Primaube, Aveyron, Frankreich, 12450
- Rekrutierung
- Maison de Santé du Sud Ruthénois
-
Kontakt:
- Denis PEREZ, MD
- Telefonnummer: 0565720606
- E-Mail: denis.perezpro@hotmail.com
-
Kontakt:
- Marie VAYSSETTES
- Telefonnummer: 0672157855
- E-Mail: marie.vayssettes@dumg-toulouse.fr
-
-
Brittany Region
-
Vannes, Brittany Region, Frankreich, 56000
- Rekrutierung
- MSP Ty santé Vannes Tohannic
-
Kontakt:
- Charlotte GRIMAULT, MD
- Telefonnummer: 0676742244
- E-Mail: charlotte.grimault@univ-nantes.fr
-
Kontakt:
- Emilie GUEGAN
- Telefonnummer: 0253526332
- E-Mail: emilie.guegan@chu-nantes.fr
-
-
Gard
-
Bezouce, Gard, Frankreich, 30320
- Rekrutierung
- Maison de Santé Pluriprofessionnelle OLEA
-
Kontakt:
- Aurélie URENA DORES, MD
- Telefonnummer: 04 13 35 45 15
- E-Mail: docteur.urenadores@hotmail.com
-
Kontakt:
- Frieda TAMOUTE
- Telefonnummer: 608869613
- E-Mail: frieda.tamoute@umontpellier.fr
-
Vergèze, Gard, Frankreich, 30310
- Rekrutierung
- MSPU la Source
-
Kontakt:
- Frieda TAMOUTE
- Telefonnummer: 608869613
- E-Mail: frieda.tamoute@umontpellier.fr
-
Kontakt:
- Chloé SIKIRDJI, MD
- Telefonnummer: 04 66 80 72 01
- E-Mail: "chloe.sikirdji@umontpellier.fr
-
-
Haute-Garonne
-
Pins-Justaret, Haute-Garonne, Frankreich, 31860
- Rekrutierung
- MSPU Pins Justaret
-
Kontakt:
- Marie VAYSSETTES
- Telefonnummer: 0672157855
- E-Mail: marie.vayssettes@dumg-toulouse.fr
-
Kontakt:
- Julie DUPOUY, MD
- Telefonnummer: 0561762700
- E-Mail: julie.dupouy@dumg-toulouse.fr
-
-
Loire Atlantiue
-
Pornic, Loire Atlantiue, Frankreich, 44210
- Rekrutierung
- Pôle de Santé et Prevention du Clion
-
Kontakt:
- Cedric Rat, MD
- Telefonnummer: 0240820075
- E-Mail: cedric.rat@univ-nantes.fr
-
Kontakt:
- Emilie Guegan
- Telefonnummer: 253526332
- E-Mail: emilie.guegan@chu-nantes.fr
-
-
New Aquitaine
-
Poitiers, New Aquitaine, Frankreich, 86021
- Rekrutierung
- CHU de Poitiers
-
Kontakt:
- Claire Bouleti, MD
- Telefonnummer: 0549444325
- E-Mail: claire.bouleti@chu-poitiers.fr
-
Kontakt:
- Marianne Hajjar
- Telefonnummer: 516604242
- E-Mail: marianne.hajjar@chu-poitiers.fr
-
-
Occitanie
-
Montpellier, Occitanie, Frankreich, 34090
- Rekrutierung
- CHU de Montpellier
-
Kontakt:
- Francois Roubille, MD
- Telefonnummer: 0467336733
- E-Mail: f-roubille@chu-montpellier.fr
-
Kontakt:
- Sonia Soltani
- E-Mail: s-soltani@chu-montpellier.fr
-
Montpellier, Occitanie, Frankreich, 34080
- Rekrutierung
- Centre Medical Villa Ravas
-
Kontakt:
- Frieda TAMOUTE
- Telefonnummer: 608869613
- E-Mail: frieda.tamoute@umontpellier.fr
-
Kontakt:
- Karolina GRIFFITHS
- E-Mail: karolina.griffiths@umontpellier.fr
-
Toulouse, Occitanie, Frankreich, 31059
- Rekrutierung
- CHU de Toulouse
-
Kontakt:
- Meyer Elbaz, MD
- Telefonnummer: 0561323649
- E-Mail: elbaz.m@chu-toulouse.fr
-
Kontakt:
- Bérangère BACHELET
- E-Mail: "bachelet.b@chu-toulouse.fr
-
Toulouse, Occitanie, Frankreich, 31500
- Rekrutierung
- Centre de santé Kersanté Toulouse La Terrasse
-
Kontakt:
- Pierrik FOSTIER
- Telefonnummer: 0582950207
- E-Mail: pierrik.fostier@wanadoo.fr
-
Toulouse, Occitanie, Frankreich, 31500
- Rekrutierung
- Maison de Santé Pluriprofessionnelle Universitaire LA PROVIDENCE
-
Kontakt:
- Marie VAYSSETTES
- Telefonnummer: 0672157855
- E-Mail: marie.vayssettes@dumg-toulouse.fr
-
Kontakt:
- Marie-Eve ROUGE-BUGAT
- Telefonnummer: 05 61 80 01 23
- E-Mail: marieeve.rouge-bugat@dumg-toulouse.fr
-
-
Occtanie
-
Nîmes, Occtanie, Frankreich, 30029
- Rekrutierung
- CHU de Nîmes
-
Kontakt:
- Guillaume Cayla, MD
- Telefonnummer: 0466683116
- E-Mail: cayla.guillaume@gmail.com
-
Kontakt:
- Chrystel LEPERCHOIS
- E-Mail: Chrystel.LEPERCHOIS@chu-nimes.fr
-
-
Pays de la Loire Region
-
Nantes, Pays de la Loire Region, Frankreich, 44093
- Rekrutierung
- CHU de Nantes
-
Kontakt:
- Bertrand CARIOU, MD
- Telefonnummer: 0253482726
- E-Mail: bertrand.cariou@univ-nantes.fr
-
Kontakt:
- Audrey ERNOULD
- Telefonnummer: 0253482726
- E-Mail: audrey.ernould@chu-nantes.fr
-
Noirmoutier-en-l'Île, Pays de la Loire Region, Frankreich, 85330
- Rekrutierung
- MSP Noirmoitier
-
Kontakt:
- Emilie GUEGAN
- Telefonnummer: 0253526332
- E-Mail: emilie.guegan@chu-nantes.fr
-
Kontakt:
- Cyrille VARTANIAN, MD
- Telefonnummer: 0244769054
- E-Mail: cyrille.vartanian@univ-nantes.fr
-
-
Seine-Saint-Denis
-
La Courneuve, Seine-Saint-Denis, Frankreich, 93120
- Rekrutierung
- CMS Salvador Allende
-
Kontakt:
- Julien LE BRETON, MD
- Telefonnummer: 01 49 92 60 60
- E-Mail: j.le.breton.com@gmail.com ; julien.le-breton@lacourneuve.fr
-
Kontakt:
- Sarah EDJEKOUANE
- Telefonnummer: 760622535
- E-Mail: s.edjekouane@cnge.fr
-
-
Yvelines
-
Poissy, Yvelines, Frankreich, 78300
- Rekrutierung
- MSPU la collégiale
-
Kontakt:
- Olivier SAINT LARY, MD
- Telefonnummer: 0185470899
- E-Mail: o.saintlary@cnge.fr
-
Kontakt:
- Sarah EDJEKOUANE
- Telefonnummer: 0760622535
- E-Mail: s.edjekouane@cnge.fr
-
-
-
-
-
Athens, Griechenland, 11528
- Rekrutierung
- Evgenidion Clinic "Agia Trias" S.A.
-
Kontakt:
- Spyridon Deftereos, MD
- Telefonnummer: +30 21 0720 8100
-
-
-
-
-
Campobasso, Italien, 86100
- Rekrutierung
- Ospedale A. Cardarelli Sc Diabetologia Ed Endocrinologia
-
Kontakt:
- Maria Rosaria Cristofaro, MD
- Telefonnummer: 0874/4091
- E-Mail: mariarosaria.cristofaro@asrem.molise.it
-
-
Apulia
-
Foggia, Apulia, Italien, 71100
- Rekrutierung
- Policlinico Riuniti U.O. Di Diabetologia
-
Kontakt:
- Olga Lamacchia, MD
- Telefonnummer: 349/4209175
- E-Mail: olga.lamacchia@unifg.it
-
Kontakt:
- Chiara Corsano, MD
- Telefonnummer: 347/2579078
- E-Mail: chiara.corsano@unifg.it
-
-
Bari
-
Acquaviva delle Fonti, Bari, Italien, 70021
- Rekrutierung
- Ospedale Miulli U.O.C. Endocrinologia
-
Kontakt:
- Lucrezia Matera, MD
- Telefonnummer: 080/3054263
- E-Mail: l.matera@miulli.it
-
-
Emilia-Romagna
-
Ferrara, Emilia-Romagna, Italien, 44100
- Rekrutierung
- Dipartimento Cure Primarie Diabetologia Territoriale
-
Kontakt:
- Marcello Monesi, MD
- Telefonnummer: 339/1494908
- E-Mail: m.monesi@ausl.fe.it
-
Ravenna, Emilia-Romagna, Italien, 48100
- Rekrutierung
- Ospedale Civile Santa Maria Delle Croci U.O. Diabetologia
-
Kontakt:
- Paolo Di Bartolo, MD
- Telefonnummer: 335/429555
- E-Mail: paolo.dibartolo@auslromagna.it
-
-
Lombardy
-
Milan, Lombardy, Italien, 20162
- Rekrutierung
- Adiabetologiasst Ospedale Metropolitano Niguarda
-
Kontakt:
- Basilio Pintaudi, MD
- Telefonnummer: 328/7858855
- E-Mail: basilio.pintaudi@ospedaleniguarda.it
-
Kontakt:
- Matteo Conti, MD
- Telefonnummer: 346/6825970
- E-Mail: matteo.conti2@ospedaleniguarda.it
-
-
Piedmont
-
Turin, Piedmont, Italien, "10122
- Rekrutierung
- "Ospedale Oftalmico S.C. Endocrinologia E Metaboliche"
-
Kontakt:
- Salvatore Oleandri, MD
- Telefonnummer: 333/6121004
- E-Mail: salvatore.oleandri@aslcittaditorino.it
-
-
The Marches
-
Ancona, The Marches, Italien, 60122
- Rekrutierung
- Ospedali Riuniti Clinica Di Cardiologia E Aritmologia
-
Kontakt:
- Giuseppe Ciliberti, MD
- Telefonnummer: 071/5965798
- E-Mail: giuseppe.ciliberti@ospedaliriuniti.marche.it
-
Kontakt:
- Niki Tombolesi
- Telefonnummer: 351/6186110
- E-Mail: niki.tombolesi@ospedaliriuniti.marche.it
-
-
Tuscany
-
Florence, Tuscany, Italien, 50124
- Rekrutierung
- Ospedale San Giovanni Di Dio, U.O. Diabetologia E Malatt. Metaboliche
-
Kontakt:
- Cristiana Baggiore, MD
- Telefonnummer: 055/7192265
- E-Mail: cristianamaria.baggiore@uslcentro.toscana.it
-
Kontakt:
- Michela Cameron Smith
- Telefonnummer: 339/7688716
- E-Mail: michela.cameronsmith@usltoscana.centro.it
-
Pisa, Tuscany, Italien, 56124
- Rekrutierung
- Ftgm - Stabilimento Di Pisa Uos Vd Attivita Ambulatoriali E Ospedale Diurno
-
Kontakt:
- Giuseppe Vergaro, MD
- Telefonnummer: 349/6105539
- E-Mail: vergaro@ftgm.it
-
Kontakt:
- Kyriazoula Chatzianagnostou
- Telefonnummer: 348/7362549
- E-Mail: zulachat@ftgm.it
-
Pistoia, Tuscany, Italien, 51100
- Rekrutierung
- Ospedale San Jacopo Sezione Di Diabetologia
-
Kontakt:
- Roberto Anichini, MD
- Telefonnummer: 338/9644876
- E-Mail: roberto.anichini@uslcentro.toscana.it
-
Kontakt:
- Chiara Delle Poggi, MD
- Telefonnummer: 338/5242866
- E-Mail: chiara.dellipoggi@uslcentro.toscana.it
-
-
-
-
Ontario
-
Toronto, Ontario, Kanada, M5B 1W8
- Rekrutierung
- St. Michael's Hospital
-
Kontakt:
- Andrew Pinto, MD
- Telefonnummer: 41613 416-864-6060
- E-Mail: andrew.pinto@utoronto.ca
-
Kontakt:
- Paolo Marcelo
- Telefonnummer: 41613 416-360-4000
- E-Mail: paolo.marcelo@unityhealth.to
-
-
Quebec
-
Montreal, Quebec, Kanada
- Rekrutierung
- Montreal Heart Institute
-
Kontakt:
- Jessica Drouin
- Telefonnummer: 3450 514-376-3330
- E-Mail: Jessica.Drouin@icm-mhi.org
-
Kontakt:
- Nancy Fernandez
- Telefonnummer: 2235 514-376-3330
- E-Mail: Nancy.Fernandez@icm-mhi.org
-
-
-
-
-
Amadora, Portugal, 2700-000
- Rekrutierung
- Unidade de Saúde Local Amadora-Sintra
-
Kontakt:
- Sergio Baptista, MD
- Telefonnummer: 962364061
- E-Mail: sergio.b.baptista@gmail.com
-
Kontakt:
- Maura Nedio
- E-Mail: maura.c.medio@ulsasi.min-saude.pt
-
Lisbon, Portugal, 1500-650
- Rekrutierung
- Hospital de Luz Lisboa
-
Kontakt:
- Anabela Raimundo, MD
- Telefonnummer: +351 936 391 728
- E-Mail: araimundo@hospitaldaluz.pt
-
Kontakt:
- Miguel Ribeiro
- Telefonnummer: +351 969 730 400
- E-Mail: miguel.rabasquinho.ribeiro@luzsaude.pt
-
Lisbon, Portugal, 1649-035
- Rekrutierung
- Unidade Local de Saue Santa Maria, EPE
-
Kontakt:
- Fausto Pinto, MD
- E-Mail: fausto.pinto@medicina.ulisboa.pt
-
Kontakt:
- Margarida Batista
- Telefonnummer: +351919682943
- E-Mail: margarida.batista@medicina.ulisboa.pt
-
-
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
-
Men and women aged 55 to 80 years
-
Type 2 diabetes treated as per national guidelines
-
No previous history of coronary artery disease-related clinical event
-
And at least one of the following:
- Duration of diabetes of 5 years or more,
- HbA1c ≥ 8.0% or more in the last 2 years
- Active cigarette smoking,
- High hs-CRP (> 2.0 mg/L),
- High coronary calcium score (Agatston score >100),
- High TG-levels (≥1.7 mmol/L) despite lipid lowering therapy administered as per guidelines,
- High LDL-C levels (≥3.5 mmol/L) or high non-HDL-C levels (≥4.2 mmol/L) despite lipid lowering therapy administered as per guidelines
- High Apo-B (≥1.05 g/L)
- Reduced HDL-C (<1.05 mmol/L in men, <1.3 mmol/L in women),
- Lp(a) >50 mg/dL,
- Peripheral artery disease with stenosis ≥50% or prior revascularization,
- Cerebrovascular disease with stenosis ≥50% or prior revascularization,
- Diabetic retinopathy or diabetic neuropathy,
- Mild or moderate proteinuria (dipstick analysis) or micro-albuminuria
-
Women of childbearing potential must have a negative urine pregnancy test at screening/randomization visit 1 and must agree to use an effective method of birth control throughout the study. Acceptable means of birth control include: oral contraceptives, implantable contraceptives, injectable contraceptives, transdermal contraceptives, intrauterine devices, male or female condoms with spermicide, abstinence, or a sterile sexual partner.
Women are considered not of childbearing potential if they either:
- Have had a hysterectomy or tubal ligation prior to baseline visit or
- Are postmenopausal defined as no menses for 12 months or a FSH level (if available) in the menopausal range.
-
Patients with the capacity to provide informed consent.
Exclusion Criteria:
-
Any prior history of myocardial infarction, angina, coronary revascularization, coronary stenosis >30%, stroke, transient ischemic attack, or known heart failure
-
Known chronic renal insufficiency defined as an estimated glomerular filtration rate (eGFR), using the MDRD equation, of < 35 mL/min/1.73m2
-
History of cancer or lymphoproliferative disease within the last 3 years other than a successfully treated non-metastatic cutaneous squamous cell or basal cell carcinoma and/or localized carcinoma in situ of the cervix and/or low-grade prostate cancer
-
Inflammatory bowel disease (Crohn's disease or ulcerative colitis) or chronic diarrhea
-
Peptic ulcer diagnosed within the last 24 months or previous gastro-intestinal bleeding, except for mild hemorrhoidal bleeding more than 5 years ago which is permitted (patients meeting this exclusion criterion will not be randomized to receive aspirin or placebo but can be randomized to receive colchicine or placebo)
-
Pre-existent progressive neuromuscular disease or known CPK level > 3 times the upper limit of normal as measured within the past 30 days and determined to be non-transient through repeat testing
-
Any of the following known parameters as measured within the past 90 days, and determined to be non-transient through repeat testing:
- hemoglobin < 100 g/L
- 2. white blood cell count < 3.0 X 10⁹/L
- platelet count <110 X 10⁹/L
- ALT > 3 times the upper limit of normal (ULN)
- total bilirubin > 2 times ULN (unless due to Gilbert syndrome, which is allowed)
-
History of cirrhosis, chronic active hepatitis or severe hepatic disease
-
Female patient who is pregnant, or breast-feeding or is considering becoming pregnant during the study or for 6 months after the last dose of study medication
-
History of clinically significant drug or alcohol abuse in the last year
-
Patient is currently using or plans to begin chronic systemic steroid therapy (oral or intravenous) during the study (topical or inhaled steroids are allowed, as well as replacement corticosteroids for adrenal insufficiency)
-
Current chronic treatment with aspirin or another antiplatelet agent (patients meeting this exclusion criterion will not be randomized to receive aspirin or placebo but can be randomized to receive colchicine or placebo)
-
Chronic treatment with an anticoagulant agent (patients meeting this exclusion criterion will not be randomized to receive aspirin or placebo but can be randomized to receive colchicine or placebo)
-
Current use of colchicine for other indications (mainly chronic indications consisting of Familial Mediterranean Fever or gout); there is no wash-out period required for patients who have been treated with colchicine and stopped treatment prior to enrolment
-
History of an allergic reaction or significant sensitivity to colchicine
-
History of an allergic reaction or significant sensitivity to aspirin (patients meeting this exclusion criterion will not be randomized to receive aspirin or placebo but can be randomized to receive colchicine or placebo)
-
Chronic treatment with an anti-inflammatory agent (for example, anti-TNF-alpha or nonsteroidal anti-inflammatory drug (NSAID))
-
Use of an investigational chemical agent less than 30 days or 5 half-lives prior to the screening visit (whichever is longer)
-
Patient is considered by the investigator, for any reason, to be an unsuitable candidate for the study.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Verhütung
- Zuteilung: Zufällig
- Interventionsmodell: Fakultätszuweisung
- Maskierung: Vervierfachen
Anzahl der Arme
Waffen und Interventionen
Teilnehmergruppe / ArmTeilnehmergruppe / Arm |
Intervention / BehandlungIntervention / Behandlung |
|---|---|
|
Aktiver Komparator: Anti-thrombotic arm
For patients eligible for aspirin therapy arm. |
40 mg non-enteric-coated tablet taken twice daily. non-enteric-coated tablet taken twice daily. 0.5 mg tablet taken once daily tablet taken once daily. |
|
Placebo-Komparator: Anti-thrombotic arm (Placebo)
For patients eligible for aspirin therapy arm. |
40 mg non-enteric-coated tablet taken twice daily. non-enteric-coated tablet taken twice daily. 0.5 mg tablet taken once daily tablet taken once daily. |
|
Aktiver Komparator: Anti-inflammatory arm
For patients ineligible for aspirin therapy arm. |
0.5 mg tablet taken once daily tablet taken once daily. |
|
Placebo-Komparator: Anti-inflammatory arm (Placebo)
For patients ineligible for aspirin therapy arm. |
0.5 mg tablet taken once daily tablet taken once daily. |
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
First event of the composite of cardiovascular death, resuscitated cardiac arrest, non-fatal myocardial infarction, non-fatal stroke, or urgent hospitalization for angina requiring coronary revascularization.
Zeitfenster: From randomization to occurrence of first event, assessed up to 60 months.
|
The number of participants having at least one of the composite of the primary endpoint. |
From randomization to occurrence of first event, assessed up to 60 months.
|
Sekundäre Ergebnismessungen
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Cardiovascular Death
Zeitfenster: From randomization to cardiovascular death, assessed up to 60 months.
|
The number of participants having a cardiovascular death. |
From randomization to cardiovascular death, assessed up to 60 months.
|
|
First Event of Resuscitated Cardiac Arrest
Zeitfenster: From randomization to event, assessed up to 60 months.
|
The number of participants having at least 1 resuscitated cardiac arrest. |
From randomization to event, assessed up to 60 months.
|
|
First Event of Non-fatal Myocardial Infarction
Zeitfenster: From randomization to event, assessed up to 60 months.
|
The number of participants having at least 1 myocardial infarction. |
From randomization to event, assessed up to 60 months.
|
|
First Event of Non-fatal Stroke
Zeitfenster: From randomization to event, assessed up to 60 months
|
The number of participants having at least 1 stroke. |
From randomization to event, assessed up to 60 months
|
|
First Occurrence of Urgent Hospitalization for Angina Requiring Coronary Revascularization
Zeitfenster: From randomization to occurrence, assessed up to 60 months.
|
The number of participants having at least 1 urgent hospitalization for angina requiring coronary revascularization. |
From randomization to occurrence, assessed up to 60 months.
|
|
First Event of Atrial Fibrillation
Zeitfenster: From randomization to event, assessed up to 60 months.
|
The number of participants having at least 1 atrial fibrillation. |
From randomization to event, assessed up to 60 months.
|
|
First Occurrence of Heart Failure Hospitalization
Zeitfenster: From randomization to occurrence, assessed up to 60 months.
|
The number of participants having at least 1 heart failure hospitalization. |
From randomization to occurrence, assessed up to 60 months.
|
|
First Occurrence of Coronary Revascularization
Zeitfenster: From randomization to occurrence, assessed up to 60 months.
|
The number of participants having at least 1 coronary revascularization. |
From randomization to occurrence, assessed up to 60 months.
|
|
MoCA Scores Assessed Over Time
Zeitfenster: From randomization to yearly follow-ups until the end-of-study visit, assessed up to 60 months.
|
Change from randomization in MoCA score at yearly follow-ups (excluding the first-year visit) until the end-of-study visit. |
From randomization to yearly follow-ups until the end-of-study visit, assessed up to 60 months.
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Studienbeginn
Primärer Abschluss (Geschätzt)
Primärer Abschluss
Studienabschluss (Geschätzt)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Erkrankungen des endokrinen Systems
- Stoffwechselerkrankungen
- Störungen des Glukosestoffwechsels
- Diabetes Mellitus
- Ernährungs- und Stoffwechselerkrankungen
- Diabetes mellitus, Typ 2
- Herz-Kreislauf-Erkrankungen
- Herzkrankheiten
- Organische Chemikalien
- Heterocyclische Verbindungen
- Kohlenwasserstoffe
- Kohlenwasserstoffe, zyklisch
- Alkaloide
- Kohlenwasserstoffe, aromatisch
- Phenole
- Benzolderivate
- Salicylate
- Hydroxybenzoates
- Aspirin
- Colchicin
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- MHICC-2021-001
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .